ONGOING PHASE 1/2 STUDY OF INCB050465, A SELECTIVE PI3Kδ INHIBITOR, FOR THE TREATMENT OF PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B‐CELL MALIGNANCIES (CITADEL‐101). (June 2017) - Caimi, P.; Ramchandren, R.; Phillips, T.J.; Wertheim, M.S.; Gutierrez, M.E.; Edenfield, W.J.; Akard, L.P.; Call, J.A.; Persky, D.O.; DeMarini, D.J.; Zhou, L.; Yeleswaram, S.; et al.